Evolution of angiotensin-converting enzyme inhibition in hypertension, heart failure, and vascular protection. (Q46022615)

18 December 2017

review article

1 reference

title

Evolution of angiotensin-converting enzyme inhibition in hypertension, heart failure, and vascular protection. (English)

1 reference

18 December 2017

1 reference

W W Parmley

1 reference

18 December 2017

language of work or name

English

0 references

publication date

1 July 1998

1 reference

18 December 2017

American Journal of Medicine

published in

1 reference

18 December 2017

volume

105

1 reference

18 December 2017

issue

1 reference

18 December 2017

page(s)

27S-31S

1 reference

18 December 2017

Clinical applications of angiotensin-converting enzyme inhibitors

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900208-3

Reversal of left ventricular hypertrophy in hypertensive patients. A metaanalysis of 109 treatment studies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900208-3

The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900208-3

Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900208-3

Effect of vasodilator therapy on mortality in chronic congestive heart failure. Results of a Veterans Administration Cooperative Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900208-3

A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900208-3

Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900208-3

Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900208-3

Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900208-3

Antiatherogenic effect of captopril in the Watanabe heritable hyperlipidemic rabbit

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900208-3

Ramipril prevents impaired endothelium-dependent relaxation in arteries from rabbits fed an atherogenic diet

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900208-3

Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease. The TREND (Trial on Reversing ENdothelial Dysfunction) Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900208-3

Role of angiotensin-converting enzyme inhibition in reversal of endothelial dysfunction in coronary artery disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900208-3

10.1016/S0002-9343(98)00208-3

7 January 2021

Identifiers

DOI

1 reference

18 December 2017

1 reference

18 December 2017